rTMS as a Treatment of Neuropathic Pain Secondary to Malignancy

Repetitive Transcranial Magnetic Stimulation in Neuropathic Pain Secondary to Malignancy.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02078479

Enrollment

Registered

2014-03-05

Start date

2010-01-31

Completion date

2013-05-31

Last updated

2014-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignancy

Keywords

Malignancy, VAS, LANSS, VDS, Neuropathic pain, rTMS, motor cortex, analgesia

Brief summary

The purpose of this study isto assess the efficacy of daily 10 sessions of rTMS over primary motor cortex in patients suffering from malignant neuropathic pain. Thirty four patients were divided randomly into 2 groups equally using closed envelops to undergo real (20 Hz, 10 second, 10 trains with inter-train interval 30 second with total pulses 2000, intensity 80% of motor threshold over hand area of motor cortex) or sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week). Patients were evaluated using a verbal descriptor scale (VDS), visual analog scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS) and Hamilton rating scale for depression (HAM-D) at baseline, after 1st, 5th, 10thtreatment session, and then 15 days and 1 month after the end of treatment. ic pain.

Interventions

PROCEDURE20 Hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week).

PROCEDUREsham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week).

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Inclusion criteria

All patients within age group 18-65 years with malignant lateralized neuropathic pain resistant to medical treatment for at least 2 months or associated with significant adverse effects from medication were involved in this study.

Exclusion criteria

Patients with intracranial metallic devices Patients with pacemakers or any other device. Patients with recent myocardial ischemia, unstable angina Patients known to have history of epilepsy.

Design outcomes

Primary

Measure	Time frame	Description
Neuropathic pain improvement	one month	Reduction of neuropathic pain in patients with malignancy measured by VDS, VAS, LANSS.

Secondary

Measure	Time frame	Description
Reduction of depression manifestation	one month	Measurement of depression by using (HAM-D) scale.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026